Literature DB >> 16174639

Amylin peptide levels are raised in infants of diabetic mothers.

V Kairamkonda1, A Deorukhkar, R Coombs, R Fraser, T Mayer.   

Abstract

BACKGROUND: Amylin is a novel 37 amino acid peptide hormone that is co-secreted with insulin from the pancreas in response to food intake. As a potent inhibitor of gastric emptying it plays an important role in the control of carbohydrate absorption. Feed intolerance is common in infants of diabetic mothers (IDM). AIMS: To establish a normal range of amylin levels in healthy neonates, and to determine whether serum amylin levels are raised in IDM.
METHODS: A serial sample of 221 infants > or =28 weeks gestation was enrolled prior to delivery over a 12 month period. Blood samples collected immediately after birth (umbilical cord), and at the routine Guthrie test were analysed for amylin and insulin levels.
RESULTS: Amylin levels in umbilical cord (n = 181) and Guthrie samples (n = 33) of healthy infants were 5.7 (3.0-9.1) and 6.9 (2.9-9.0) pmol/l respectively. IDM had significantly raised amylin levels in both cord (n = 31; 32.7 pmol/l, 25.9-48.1) and Guthrie samples (n = 8; 18.1 pmol/l, 15.3-23.6). Amylin correlated positively with insulin (n = 42; r = 0.67; 95% CI 0.4 to 0.81), birth weight (r = 0.22; 95% CI 0.08 to 0.36), and gestation (r = 0.18; 95% CI 0.03 to 0.32). Umbilical cord venous amylin levels showed agreement with arterial cord amylin levels (n = 34, mean bias -0.2, 95% CI 3.1 to -3.6).
CONCLUSIONS: Amylin levels are significantly increased in the umbilical cord and Guthrie blood samples in IDM.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16174639      PMCID: PMC1720202          DOI: 10.1136/adc.2005.078238

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  19 in total

Review 1.  Islet amyloid and type 2 diabetes mellitus.

Authors:  J W Höppener; B Ahrén; C J Lips
Journal:  N Engl J Med       Date:  2000-08-10       Impact factor: 91.245

2.  Amylin concentrations and glucose control.

Authors:  J E Koda; M Fineman; T J Rink; G E Dailey; D B Muchmore; L G Linarelli
Journal:  Lancet       Date:  1992-05-09       Impact factor: 79.321

3.  Islet amyloid polypeptide response to glucose, insulin, and somatostatin analogue administration.

Authors:  T Mitsukawa; J Takemura; J Asai; M Nakazato; K Kangawa; H Matsuo; S Matsukura
Journal:  Diabetes       Date:  1990-05       Impact factor: 9.461

Review 4.  Central amylin signaling and the regulation of energy homeostasis.

Authors:  Paul A Rushing
Journal:  Curr Pharm Des       Date:  2003       Impact factor: 3.116

5.  Calcitonin gene-related peptide and other neuropeptides in the plasma of patients with soft tissue injury.

Authors:  G N Onuoha; E K Alpar
Journal:  Life Sci       Date:  1999       Impact factor: 5.037

Review 6.  Diabetic pregnancy and perinatal morbidity.

Authors:  J L Kitzmiller; J P Cloherty; M D Younger; A Tabatabaii; S B Rothchild; I Sosenko; M F Epstein; S Singh; R K Neff
Journal:  Am J Obstet Gynecol       Date:  1978-07-01       Impact factor: 8.661

7.  Calcitonin gene-related peptide levels are elevated in patients with sepsis.

Authors:  C D Joyce; R R Fiscus; X Wang; D J Dries; R C Morris; R A Prinz
Journal:  Surgery       Date:  1990-12       Impact factor: 3.982

8.  Plasma islet amyloid polypeptide (Amylin) levels and their responses to oral glucose in type 2 (non-insulin-dependent) diabetic patients.

Authors:  T Sanke; T Hanabusa; Y Nakano; C Oki; K Okai; S Nishimura; M Kondo; K Nanjo
Journal:  Diabetologia       Date:  1991-02       Impact factor: 10.122

9.  Amylin is associated with delayed gastric emptying in critically ill children.

Authors:  Anton-Paul T Mayer; Andrew Durward; Charles Turner; Sophie Skellett; Neil Dalton; Shane M Tibby; Ian A Murdoch
Journal:  Intensive Care Med       Date:  2002-02-08       Impact factor: 17.440

Review 10.  [Amylin--its physiological role in humans].

Authors:  J Bronský; M Chada; K Kotaska; R Průsa
Journal:  Cesk Fysiol       Date:  2002-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.